EG545802 Inhibitors
Hectd4, a HECT domain E3 ubiquitin protein ligase, is predicted to play a role in glucose homeostasis and the glucose metabolic process. Its expression in various structures, including the extraembryonic component, nervous system, neural retina, reproductive system, and tongue, suggests a broad involvement in physiological processes. While the precise function of Hectd4 remains unknown, the predicted association with glucose-related processes positions it as a potential regulator in metabolic homeostasis. Inhibition of Hectd4 can be achieved through both direct and indirect means, leveraging a variety of chemical compounds. Direct inhibitors such as MG-132, Bortezomib, and MLN7243 target the proteasome, preventing the degradation of Hectd4 and leading to its accumulation. Indirect inhibitors like MLN4924, Pevonedistat, and Thalidomide impact Hectd4 through modulation of the NEDD8-activating enzyme (NAE) or CRBN pathways, influencing the activation and stability of Hectd4. Other compounds like Nutlin-3 and WP1130 indirectly regulate Hectd4 levels by interfering with the p53-MDM2 interaction or targeting the deubiquitinase USP9X, respectively.
Furthermore, chemicals like ATRA and C646 influence Hectd4 through modulation of gene expression, affecting the levels of this ubiquitin ligase. The AMP-activated protein kinase (AMPK) activator, AICAR, indirectly impacts Hectd4 by modulating cellular energy status through AMPK activation. These diverse mechanisms highlight the complex regulatory networks that may govern Hectd4's involvement in glucose homeostasis and metabolic processes. The specific roles and regulatory pathways associated with Hectd4 warrant further exploration to elucidate its exact contribution to cellular physiology and its potential implications in metabolic homeostasis.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor. MG-132 directly inhibits Hectd4 by preventing the proteasomal degradation of this E3 ubiquitin ligase. This inhibition leads to the accumulation of Hectd4, disrupting its predicted functions in glucose homeostasis and the glucose metabolic process. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
NEDD8-activating enzyme (NAE) inhibitor. MLN4924 indirectly inhibits Hectd4 by blocking the neddylation pathway, essential for the activation of cullin-RING ligases (CRLs) including Hectd4. This interference results in the inactivation of Hectd4, impacting its role in ubiquitin-mediated processes related to glucose homeostasis. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Cereblon (CRBN) modulator. Thalidomide indirectly inhibits Hectd4 by modulating the CRBN pathway, influencing the ubiquitin-proteasome system. This modulation leads to alterations in Hectd4 levels, impacting its predicted functions in glucose homeostasis and the glucose metabolic process. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
MDM2 inhibitor. Nutlin-3 indirectly inhibits Hectd4 by disrupting the MDM2-p53 interaction, resulting in the stabilization of p53. The stabilized p53 then negatively regulates Hectd4 expression, impacting its role in glucose homeostasis and the glucose metabolic process. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor. Bortezomib directly inhibits Hectd4 by preventing the proteasomal degradation of this E3 ubiquitin ligase. This inhibition leads to the accumulation of Hectd4, disrupting its predicted functions in glucose homeostasis and the glucose metabolic process. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Cereblon (CRBN) modulator. Lenalidomide indirectly inhibits Hectd4 by modulating the CRBN pathway, influencing the ubiquitin-proteasome system. This modulation leads to alterations in Hectd4 levels, impacting its predicted functions in glucose homeostasis and the glucose metabolic process. | ||||||
MLN7243 | 1450833-55-2 | sc-507338 | 5 mg | $340.00 | ||
NEDD8-activating enzyme (NAE) inhibitor. MLN7243 indirectly inhibits Hectd4 by blocking the neddylation pathway, essential for the activation of cullin-RING ligases (CRLs) including Hectd4. This interference results in the inactivation of Hectd4, impacting its role in ubiquitin-mediated processes related to glucose homeostasis. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid receptor agonist. ATRA indirectly inhibits Hectd4 by influencing the retinoic acid signaling pathway, which can modulate gene expression. The altered gene expression profile may include changes in Hectd4 levels, impacting its predicted functions in glucose homeostasis and the glucose metabolic process. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
p300/CBP inhibitor. C646 indirectly inhibits Hectd4 by targeting the histone acetyltransferase activity of p300/CBP, key regulators of gene expression. This inhibition leads to changes in the acetylation status of histones, potentially affecting Hectd4 expression and impacting its predicted functions in glucose homeostasis and the glucose metabolic process. | ||||||
WP1130 | 856243-80-6 | sc-364650 sc-364650A | 10 mg 50 mg | $490.00 $1484.00 | 1 | |
USP9X inhibitor. WP1130 indirectly inhibits Hectd4 by targeting the deubiquitinase USP9X, which regulates the stability of Hectd4. Inhibition of USP9X leads to increased ubiquitination and degradation of Hectd4, impacting its predicted functions in glucose homeostasis and the glucose metabolic process. | ||||||